Loading…
Medical Testing Availability Act of 2013
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,821 other HR bills in the 113th — cohort avg 49d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2013 · fourth_quarter · Medical/Disease Research/Clinical Labs
H.R. 3005: Medical Testing Availablity Act of 2013; Provisions regarding FDA regulations of certain diagnostics and lab developed tests. Draft and final guidance regarding commercially distributed in vitro diagnostic products labeled "For Research Only" or "Investigational Use Only"; Provisions regarding FDA regulation of certain diagnostics.H.R. 2085: Diagnostic Innovation Testing and Knowledge Advancement Act of 2013; Provisions regarding value based payment for advanced diagnostics.
Client expense: $50,000 · Firm income: Not reported
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Medical/Disease Research/Clinical Labs
H.R. 3005: Medical Testing Availablity Act of 2013; Provisions regarding FDA regulations of certain diagnostics and lab developed tests. Draft and final guidance regarding commercially distributed in vitro diagnostic products labeled "For Research Only" or "Investigational Use Only"; Provisions regarding FDA regulation of certain diagnostics.H.R. 2085: Diagnostic Innovation Testing and Knowledge Advancement Act of 2013; Provisions regarding value based payment for advanced diagnostics.
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2013 · third_quarter · Medical/Disease Research/Clinical Labs
H.R. 3005: Medical Testing Availablity Act of 2013; Provisions regarding FDA regulations of certain diagnostics and lab developed tests. Draft guidance regarding commercially distributed in vitro diagnostic products labeled "For Research Only or Investigational Use Only:" Frequently Asked Questions; Provisions regarding regulation of certain diagnostics.H.R. 2085: Diagnostic Innovation Testing and Knowledge Advancement Act of 2013; Provisions regarding value based payment for advanced diagnostics.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| CA |
| Kay Granger | Republican | TX |
| Michael M. Honda | Democratic | CA |
| Scott H. Peters | Democratic | CA |